Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNC1 | P63316 | 5/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.47 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | TACR2 | P21452 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042932 | 0.88 | TNNC1 (0.44) | TNNC1S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL903515 | 0.81 | S1PR1 (0.61) | TNNC1S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL15960544 | 0.79 | TNNC1 (0.50) | TNNC1S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL10037548 | 0.78 | NPC1 (0.39) | KDM4EALDH1A1LMNAHSD17B10ACHE | |
| SCHEMBL5847049 | 0.78 | S1PR1 (0.64) | TNNC1S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL8499542 | 0.78 | S1PR1 (0.64) | TNNC1S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL27997928 | 0.77 | TNNC1 (0.46) | TNNC1S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL10036574 | 0.77 | S1PR1 (0.56) | TNNC1S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL5846363 | 0.77 | TNNC1 (0.46) | TNNC1S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL8495841 | 0.77 | TNNC1 (0.46) | TNNC1S1PR1S1PR4S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632889-B1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD (IL) | 2018-08-29 | — | — | EP | disclosed |
| EP-2621886-B1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON BV (NL) | 2018-05-02 | — | — | EP | disclosed |
| EP-3092222-B1 | IMPROVED FINGOLIMOD PROCESS | EMCURE PHARMACEUTICALS LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3092222-A1 | IMPROVED FINGOLIMOD PROCESS | Emcure Pharmaceuticals Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| US-9216943-B2 | Preparation of fingolimod and its salts | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-22 | — | — | US | disclosed |
| US-9216943-B2 | Preparation of fingolimod and its salts | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-22 | — | — | US | disclosed |
| WO-2015107548-A1 | IMPROVED FINGOLIMOD PROCESS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| US-20140235895-A1 | PREPARATION OF FINGOLIMOD AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235895-A1 | PREPARATION OF FINGOLIMOD AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-08-21 | — | — | US | disclosed |
| US-8735627-B2 | Intermediate compounds and process for the preparation of fingolimod | MAPI PHARMA LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| WO-2012056458-A2 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012056458-A2 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012041359-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041405-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041405-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041359-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041707-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON BV (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041707-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON BV (NL) | 2012-04-05 | — | — | WO | disclosed |
| CN-1310869-C | 2-amido-2-[2-(4-alkylphenyl)ethyl]-1,3-methyl glycol preparation method | JIANGSU WUZHONG PHARMACEUTICAL (CN) | 2007-04-18 | — | — | CN | disclosed |
| CN-1765872-A | 2-amido-2-[2-(4-alkylphenyl)ethyl]-1,3-methyl glycol preparation method | JIANGSU WUZHONG PHARMACEUTICAL (CN) | 2006-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235895-A1 | PREPARATION OF FINGOLIMOD AND ITS SALTS | S1PR4, S1PR2, S1PR1 | TNNC1 4008/4885S1PR1 3/4885S1PR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.